Rodman & Renshaw

Rodman & Renshaw Recent News

Synergy Pharma's Plecanitide Finally Crosses The Finish Line; Rodman & Renshaw Lifts Price Target To $18
Rodman & Renshaw Gives Gevo $12 Price Target, Reflects On Progress
Synergy Hits Endpoints, Earns A Price Target Bump At Rodman & Renshaw
Synergy Pharma's Chief Strategist Discusses Recent Results And Coming Catalysts
Eyegate CEO Discusses De Novo Pathway For Therapeutic Eye Drops
With Valeant's Continued Deterioration, Rodman & Renshaw Downgrades To Neutral
Rodman & Renshaw Sets New Buy Rating On Abraxas Petroleum
TearLab's Co-Promotion With PRN A Positive, But Rodman & Renshaw Isn't Raising Its Estimates
Resolute Energy Initiated At Buy Given 'Impressive' Permian Basin Potential
Rodman & Renshaw Prescribe A $6 Price Target For Cancer Genetics
Sum-Of-The-Parts Valuation Leads Rodman & Renshaw To Initiate Oasmia Pharmaceuticals At Buy With A $6 Target
Rodman & Renshaw Sees 52% Upside In Hecla Mining
Ring Energy's Business Model Well-Suited For This Oil Price Environment, Says Rodman & Renshaw
HTG Molecular's Profiling System 'Requires Less But Delivers More'
5 Stocks Under $5 Making Headlines
Rodman & Renshaw Sees 243% Upside In OncoSec Medical Shares
Rodman & Renshaw Initiates Orion Energy At Buy, Attaches $2.50 Target
Why This Analyst Sees TearLab Shares Tripling
Valeant Crossed $20 Today; Rodman & Renshaw Sees Shares Getting To $90
Rodman & Renshaw Sees 160% Upside For NeuroMetrix
Further Growth Projected At LabStyle Innovations
Here's Why Presbia Is Worth $14/Share, Despite Plummeting Monday
Rodman & Renshaw: Allow For Lower Margin Customer Attrition In Just Energy Group